Entos Pharmaceuticals Inc.

14 records totalling $88,806,102.07 CAD, from official Government of Canada open data.

Embed this chart

Lobbying registry — possible match matched by name

An organization with this name appears in 38 federal lobbying registrations (0 currently active), between 2020 and 2026.

946789-367391-15 946789-367391-14 946789-367391-13

Matched automatically by organization name; a different organization with the same name is possible. The Registry of Lobbyists is the authoritative source. Lobbying is legal and regulated — this is context, not an allegation.

By department

Records

Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada
SIF Stream2- Growth
FY 2024-2025
Canada

This project will support the establishment of an innovation research and development (R&D) centre and a commercial scale, good manufacturing practices (GMP) manufacturing facility in Edmonton, Albert...

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2020-2021
Canada

Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine...

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2022-2023
Canada

Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001-1c biva...

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2021-2022
Canada

Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine...

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2025-2026
Canada

Seasonal and pandemic influenza continue to pose substantial threats to public health and highly pathogenic strains such as H5N1 carry the potential for devastating outbreaks. The Firm proposes to dev...

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2025-2026
Canada

In partnership with a large Multinational Pharmaceutical Partner, the Firm will evaluate the safety and effectiveness of its Fusogenix formulations optimized for delivery of genetic medicines to the t...

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2025-2026
Canada

As part of the international consortium project “NPmsDNA2024: Development of in vivo targeted non-viral gene therapies” this project will focus on leveraging Entos’ Fusogenix PLV formulations optimize...

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2018-2019
Canada

The goal of this project is to establish a method to synthesize Fusogenix DNA lipid nanoparticles using a single step manufacturing process. To achieve this, we will evaluate a number of methods to in...

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2020-2021
Canada

This project utilizes the Entos Fusogenix DNA delivery platform to rapidly develop, validate, manufacture and deploy countermeasures to protect the majority of the Canadian population from SARS-CoV-2...

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2024-2025
Canada

As part of Multinational Corporate Collaboration Program, the project “Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye” will focus on the evaluation o...

Global Affairs Canada | Affaires mondiales Canada
Canadian International Innovation Program (CIIP)
FY 2023-2024
Canada

The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research...